Vesicular Glutamate Transporter 2 (VGLUT2) Protein
Introduction Slc17A6 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-protein"> [@schenck2009]
Overview ...
Vesicular Glutamate Transporter 2 (VGLUT2) Protein
Introduction Slc17A6 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-protein"> [@schenck2009]
Overview Vesicular Glutamate Transporter 2 (VGLUT2) , encoded by the SLC17A6 gene, is a proton-coupled glutamate transporter that packages glutamate into synaptic vesicles[@shigeri2004]. VGLUT2 is the primary vesicular glutamate transporter in subpopulations of excitatory [neurons](/entities/neurons) throughout the brain, particularly in thalamus, brainstem, and subcortical structures. By mediating glutamate uptake into synaptic vesicles, VGLUT2 is essential for glutamatergic neurotransmission and is implicated in various neurological and neurodegenerative disorders.
Structure
Domain Architecture VGLUT2 contains 12 transmembrane domains characteristic of the SLC17 family:
N-terminus : Cytoplasmic, contains trafficking signalsTransmembrane helices 1-12 : Form the translocation pathwayExtracellular loops : Loop C contains key substrate-binding residuesC-terminus : Cytoplasmic, contains PDZ-binding motifTransport Mechanism VGLUT2 uses a proton gradient to drive glutamate uptake[@schenck2009]:
Proton binding : Protons from the vesicular lumen bind to VGLUT2Glutamate binding : Cytoplasmic glutamate binds to the transporterConformational change : Transporter shifts from outward to inward-facingRelease : Glutamate and protons released into the vesicle lumenRecycling : Transporter returns to initial state
Substrate Specificity | Substrate | Affinity (Km) | Notes |
Normal Function
Glutamatergic Neurotransmission VGLUT2 is essential for packing glutamate into synaptic vesicles[^3]:
Vesicular loading : Concentrates glutamate ~10,000-fold in vesiclesQuantal size : Determines glutamate amount per vesicleSynaptic efficacy : VGLUT2 expression level affects transmission strengthCo-transmission : May package other neuromodulatorsBrain Distribution VGLUT2 is expressed in glutamatergic neurons:
Thalamus : All thalamic relay neuronsBrainstem : Pontine nuclei, inferior olive, red nucleusSubcortical structures : Basal ganglia output nucleiCerebellum : Granule cells (VGLUT1 also)Hypothalamus : Several nuclei[Cortex](/brain-regions/cortex) : Layer 5 pyramidal cells (some)Comparison with Other VGLUTs | VGLUT | Primary Expression | Function |
Expression Pattern
Developmental Regulation
Embryonic : Early expression in developing brainPostnatal : Increases dramatically around P10-14Adult : Stable expression in mature neuronsCellular Localization
Synaptic vesicles : Concentrated in clear synaptic vesiclesPresynaptic active zone : Near release sitesDendrites : Dendritic vesicle pools in some neuronsRole in Neurodegeneration
Alzheimer's Disease VGLUT2 alterations in AD[^4]:
Glutamatergic dysfunction : Altered VGLUT2 in AD thalamusExcitotoxicity : May contribute to excitotoxic damageThalamic involvement : Early thalamic pathology in ADParkinson's Disease
Thalamic changes : VGLUT2 neurons in PD thalamus affectedExcessive glutamate : Potential contributor to dyskinesiaSubthalamic nucleus : High VGLUT2 expressionAmyotrophic Lateral Sclerosis (ALS)
Motor neuron vulnerability : VGLUT2 in ALS modelsExcitotoxic mechanisms : Glutamate dysregulationTherapeutic target : VGLUT2 modulators in developmentEpilepsy
Seizure susceptibility : Altered VGLUT2 expressionGlutamate homeostasis : Imbalance contributes to seizuresTherapeutic potential : VGLUT2 as targetTherapeutic Targeting
Drug Development | Approach | Mechanism | Status |
Challenges
Essential function : Complete loss is lethalExpression pattern : Broad throughout brainCompensation : Other VGLUTs can compensateAnimal Models
VGLUT2 knockout mice : Die shortly after birthConditional knockouts : Reveal region-specific functionsHeterozygotes : Viable, show subtle deficitsResearch Directions
Single-cell sequencing : VGLUT2 neuron subtypesCircuit mapping : Input-output relationshipsDisease biomarkers : VGLUT2 as indicatorOptogenetics : VGLUT2 promoter for targetingBackground The study of Slc17A6 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
SLC17A6 Gene
[VGLUT1 Protein](/proteins/vglut1-protein)
[VGLUT3 Protein](/proteins/vglut3-protein)
[Glutamate Signaling](/mechanisms/glutamate-signaling)
[Thalamus](/brain-regions/thalamus)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
External Links
[UniProt Q9P1U1](https://www.uniprot.org/uniprot/Q9P1U1)
[PDB: 5W5U](https://www.rcsb.org/structure/5W5U)
[Human Protein Atlas](https://www.proteinatlas.org/ENSG00000117586-SLC17A6)
[Brain RNAseq](https://www.brainrnaseq.org/)
References
Shigeri Y, et al, (2004) (2004)
Schenck S, et al, (2009) (2009) Show full description